India's PLI scheme to fuel 50 new pharma plants

India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices.

This adds to the 50 plants already established under the scheme, according to a senior government official, which have played a crucial role in boosting India's pharmaceutical exports to $10 billion, particularly to countries with stringent regulatory standards, reports The Pharma Letter’s India correspondent.

To enhance domestic production of crucial bulk drugs, reduce reliance on imports, and fortify the supply chain, the Indian government approved the PLI scheme. The phase 2 of the scheme, with a substantial financial outlay of $828 million, aims to bolster domestic manufacturing of critical key starting materials (KSMs), drug Intermediates (DI), and active pharmaceutical ingredients (APIs).